Navigation Links
Novavax Reports First Quarter 2009 Financial Results
Date:5/8/2009

ROCKVILLE, Md., May 8 /PRNewswire-FirstCall/ - Novavax Inc. (Nasdaq: NVAX) today announced financial results for the first quarter of 2009. Novavax reported a net loss of $8.3 million, or $0.12 per share, for the first quarter of 2009 compared to a net loss of $7.8 million, or $0.13 per share, for the first quarter of 2008. The Company spent a total of $7.4 million in the first quarter of 2009 and ended the quarter with $25.6 million in cash and short-term investments. During the quarter, the Company made significant progress in developing its vaccine pipeline, improved its balance sheet by raising capital and retiring a majority of its convertible debt, and completed a transaction with Cadila Pharmaceutical Limited to create a Joint Venture Company in India.

Specifically accomplishments since the 2008 year end financial results include the following:

  • Commenced development of a VLP vaccine candidate against the novel influenza A (H1N1) virus that has recently emerged in the United States and Mexico.
  • Publication of results in the Journal of Virology from preclinical studies conducted under a collaborative research and development agreement (CRADA) between the Centers for Disease Control and Prevention (CDC) and Novavax showing that an investigational H1N1 VLP vaccine based on the 1918 Spanish influenza strain protected against both the Spanish flu and a highly pathogenic H5N1 avian influenza strain.
  • Announced the initiation of enrollment in the second Phase II study of its trivalent seasonal influenza VLP vaccine candidate. This clinical trial is designed to evaluate the safety and immunogenicity of a broader range of vaccine doses and to provide data to help select doses for future studies in older adults and a Phase III efficacy study. The Company plans to report top-line immunogenicity and safety results from this study by the fourth quarte
    '/>"/>

SOURCE Novavax, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Novavax Announces Enrollment in the Second Phase II Study of its Seasonal Influenza VLP Vaccine Candidate
2. Novavax Announces Release Date of 2009 First Quarter, Financial Results and Investor Conference Call
3. Novavax Announces Early Retirement of $17 Million of Convertible Debt
4. NOVAVAX Announces Publication of a Preclinical Study Demonstrating that a Virus-like Particle Vaccine Provided Protection Against Highly Pathogenic H1N1 and H5N1 Influenza Strains
5. Novavax Announces New Capital Infusion Through a Strategic Alliance with Cadila Pharmaceuticals of India
6. Novavax Announces New Release Date of 2008 Fourth Quarter Financial Results and Investor Conference Call
7. Novavax Announces Release Date of 2008 Fourth Quarter Financial Results and Investor Conference Call
8. Novavax to Present at Cowen and Company 29th Annual Healthcare Conference
9. NOVAVAX Announces Preclinical Study Results for a Respiratory Syncytial Virus (RSV) Vaccine Candidate Directed Against the Fusion (F) Protein
10. Novavax and Vivalis Sign a Research License Agreement to Use the EB66(R) Cell Line for the Production of Virus Like Particle Based Vaccines
11. Novavax Announces Operational Status of Its Vaccine Pilot Plant and Commercial Launch Facility
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... On October 26th at the Mid ... leading applied stem cell research scientist Neil Riordan, ... talks on New Techniques for Enhancing Stem Cell ... Cells. , Dr. Riordan focused on historical medical ... AlphaGEMS that include: wound healing; inflammation and pain ...
(Date:10/30/2014)... Diego, CA (PRWEB) October 30, 2014 ... announced today that they have manually curated public data ... and non profit customers. the data is now ... manually curates and unifies public and internal data sources ... value and knowledge out of the data that becomes ...
(Date:10/30/2014)... Ottawa, Ontario (PRWEB) October 30, 2014 ... the Spartan RX CYP2C19 System . It detects ... a non-invasive cheek swab. , The Spartan RX CYP2C19 ... medicine that has been approved in Canada. Due to ... that it may be used by healthcare professionals such ...
(Date:10/30/2014)... (PRWEB) October 30, 2014 Avure Technologies celebrates ... 525L, the newest member of its fleet of high volume ... reaching an anniversary as we return to PackExpo this year, ... ago in Las Vegas,” said Jeff Williams, CEO at Avure. ... and we’re pleased to be meeting the challenges of market ...
Breaking Biology Technology:Riordan-McKenna Institute Founders, Neil Riordan, PhD and Orthopedic Surgeon, Dr. Wade McKenna Present at the Mid American Regenerative and Cellular Medicine Showcase 2Riordan-McKenna Institute Founders, Neil Riordan, PhD and Orthopedic Surgeon, Dr. Wade McKenna Present at the Mid American Regenerative and Cellular Medicine Showcase 3Riordan-McKenna Institute Founders, Neil Riordan, PhD and Orthopedic Surgeon, Dr. Wade McKenna Present at the Mid American Regenerative and Cellular Medicine Showcase 4Rancho BioSciences Manually Curated TCGA Data Sets Available 2Health Canada approves first near-patient DNA test for personalized medicine 2Health Canada approves first near-patient DNA test for personalized medicine 3In High Demand: New High Pressure Processing (HPP) System with Maximum Throughput Drives Strong Sales 2In High Demand: New High Pressure Processing (HPP) System with Maximum Throughput Drives Strong Sales 3
... McCormick School of Engineering and Applied Science at Northwestern ... of probe used in atomic force microscopy (AFM), which ... Using diamond, researchers made a much more durable ... are typically used in AFM to gather information from ...
... YM BioSciences Inc. (NYSE Amex: YMI, TSX: YM), a ... a diverse portfolio of promising cancer-related products at various ... for the first quarter of fiscal 2010, ended September ... continued to advance our lead drug nimotuzumab, which is ...
... KVISTGARD, Denmark, November 11 Today Bavarian Nordic published ... including the financial statements is available on the company,s ... months of 2009 Bavarian Nordic generated revenue of DKK ... DKK 261 million. As of 30 September 2009 the ...
Cached Biology Technology:New nanocrystalline diamond probes overcome wear 2YM BIOSCIENCES REPORTS FISCAL FIRST QUARTER 2010 OPERATIONAL AND FINANCIAL RESULTS 2YM BIOSCIENCES REPORTS FISCAL FIRST QUARTER 2010 OPERATIONAL AND FINANCIAL RESULTS 3YM BIOSCIENCES REPORTS FISCAL FIRST QUARTER 2010 OPERATIONAL AND FINANCIAL RESULTS 4YM BIOSCIENCES REPORTS FISCAL FIRST QUARTER 2010 OPERATIONAL AND FINANCIAL RESULTS 5YM BIOSCIENCES REPORTS FISCAL FIRST QUARTER 2010 OPERATIONAL AND FINANCIAL RESULTS 6YM BIOSCIENCES REPORTS FISCAL FIRST QUARTER 2010 OPERATIONAL AND FINANCIAL RESULTS 7YM BIOSCIENCES REPORTS FISCAL FIRST QUARTER 2010 OPERATIONAL AND FINANCIAL RESULTS 8YM BIOSCIENCES REPORTS FISCAL FIRST QUARTER 2010 OPERATIONAL AND FINANCIAL RESULTS 9YM BIOSCIENCES REPORTS FISCAL FIRST QUARTER 2010 OPERATIONAL AND FINANCIAL RESULTS 10YM BIOSCIENCES REPORTS FISCAL FIRST QUARTER 2010 OPERATIONAL AND FINANCIAL RESULTS 11YM BIOSCIENCES REPORTS FISCAL FIRST QUARTER 2010 OPERATIONAL AND FINANCIAL RESULTS 12Bavarian Nordic A/S - Interim Report for the Period 1 January to 30 September 2009 2Bavarian Nordic A/S - Interim Report for the Period 1 January to 30 September 2009 3Bavarian Nordic A/S - Interim Report for the Period 1 January to 30 September 2009 4Bavarian Nordic A/S - Interim Report for the Period 1 January to 30 September 2009 5
(Date:10/30/2014)... North Carolina State University researchers have developed a suite ... between dogs and humans, which has applications in everything ... our pets. , "We,ve developed a platform for computer-mediated ... to new avenues for interpreting dogs, behavioral signals and ... Dr. David Roberts, an assistant professor of computer science ...
(Date:10/29/2014)... by unconventional oil and gas production are well over ... the open access journal Environmental Health . High ... The study is the first to be based on ... and could be used to supplement official air-quality monitoring ... that do not readily flow to the surface. This ...
(Date:10/29/2014)... (October 29, 2014, Beaverton, OR) New research ... 11th International Conference in Houston, TX showed for ... eliminate HPV infection in women using a readily ... The study, presented by Dr. Judith A. Smith, ... Gynecology and Reproductive Sciences at The University of ...
Breaking Biology News(10 mins):New tech aims to improve communication between dogs and humans 2Air quality and unconventional oil and gas sites 2Air quality and unconventional oil and gas sites 3HPV infections in women eradicated by AHCC, Japanese mushroom extract 2
... at the University of Warwick's plant research arm Warwick ... develop a butterfly farming industry in Guyana that will ... help save the rainforest itself. , The University of ... for Rain Forest Conservation in Guyana. The conservation reserve ...
... A massive dinosaur death bed in Alberta has helped map ... theories about how one species lived, says new research conducted ... the surprises to me was that the overall pattern of ... catastrophic model we were expecting," said world-renowned paleontologist Dr. Phillip ...
... The regions in robins' brains responsible for singing and mating ... new University of Alberta research--the first proof that natural exposure ... , "These residues have been persisting since the late ... post-doctoral research fellow in the U of A's Department of ...
Cached Biology News:Butterfly farming to help save rain forest 2Tyrannosaur survivorship -- tough times for teens 2Bird brains shrink from exposure to contaminants 2
Bethyl Laboratories packages antibodies, conjugates and calibrators to provide quantitative ELISA kits. Each kit contains the following components, sufficient for 1000 single well assays....
QML offers standard and customized paraffin embedded tissue blocks....
... include: ,ISH Protocol Development ,Probe ... ,RNA and DNA Screenings in ... Tissues ,Double Labeling of RNA ... Tissues ,RNA and DNA Localization ...
... involves the optimization of immunostaining. ... of the primary antibody, selection ... (e.g. Alk. Phos., HRP, fluorescence, ... detection, evaluation by light or ...
Biology Products: